Heterologous Expression, Purification, and Characterization of the HspX, Ppe۴۴, and EsxV Proteins of Mycobacterium tuberculosis

Publish Year: 1397
نوع سند: مقاله ژورنالی
زبان: English
View: 104

This Paper With 6 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_RBMB-6-2_002

تاریخ نمایه سازی: 10 شهریور 1400

Abstract:

Background: Subunit vaccines are appropriate vaccine candidates for the prevention of some infections. In this study, three immunogenic proteins of Mycobacterium tuberculosis, including HspX, Ppe۴۴, and EsxV as a new construction, were expressed alone and as a fusion protein to develop a new vaccine candidate against tuberculosis infection. Methods: To make the fusion protein, the three genes were linked together by AEAAAKEAAAKA linkers and inserted into pET۲۱b and pET۳۲b vectors. Escherichia coli (E. coli) Top۱۰ cells were transformed with the plasmid, and the purified plasmid was used to transform E. coli BL۲۱ cells. Protein expression was induced with IPTG. After optimizing protein expression, the recombinant proteins were purified by Ni-NTA chromatography. Protein purification was confirmed by SDS-PAGE and Western blotting with an anti-poly histidine-peroxidase monoclonal antibody against the ۶His–tags at the proteins’ C termini. Results: Directional cloning was confirmed by polymerase chain reaction (PCR), restriction enzyme digestion, and sequencing. The highest expression of the tri-fusion protein and HspX were obtained by the addition of ۰.۲ mM of IPTG to E. coli BL-۲۱ cells at ۳۷ ˚C and ۱۸ h of incubation. For Ppe۴۴ and EsxV, the optimum expression conditions were ۱۸ ˚C and ۱۶ h of incubation. SDS-PAGE and Western blots confirmed that the desired proteins were produced. Conclusions: The three desired proteins and the fusion protein were successfully expressed and the conditions for optimum expression determined. These recombinant proteins will be evaluated as vaccine candidates against tuberculosis. Further studies are needed to evaluate the abilities of these proteins to induce strong immunological responses.

Authors

Yousef Amini

Microbiology & Virology Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Mohsen Tafaghodi

Nanotechnology Research Center, Pharmaceutical Department, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Saied Amel Jamehdar

Microbiology & Virology Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

zahra Meshkat

Microbiology & Virology Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Bagher Moradi

Microbiology & Virology Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Mojtaba Sankian

Immunology Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Kochi A. Tuberculosisdistribution, risk factors, mortality. Immunobiology. ۱۹۹۴;۱۹۱(۴):۳۲۵-۳۳۶ ...
  • Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, ...
  • Skeiky YAW, Sadoff JC. Advances in tuberculosis vaccine strategies. Nature ...
  • Wang L, Shi C, Fan X, Xue Y, Bai Y, ...
  • Young DB, Stewart GR. Tuberculosis vaccines. British medical bulletin. ۲۰۰۲; ...
  • Andersen P. TB vaccines: progress and problems. Trends in immunology. ...
  • Babiuk LA. Broadening the approaches to developing more effective vaccines. ...
  • Brown F. Peptide vaccines: fantasy or reality?World Journal of Microbiology ...
  • Levine MM, Sztein MB. Vaccine development strategies for improving immunization: ...
  • Siddiqui KF, Amir M, Agrewala JN. Understanding the biology of ...
  • He X-Y, Zhuang Y-H, Zhang X-G, Li G-L. Comparative proteome ...
  • Mattow J, Schaible UE, Schmidt F, Hagens K, Siejak F, ...
  • Målen H, Berven FS, Fladmark KE, Wiker HG. Comprehensive analysis ...
  • Hanif S, Al‐Attiyah R, Mustafa A. Molecular Cloning, Expression, Purification ...
  • Ansari MA, Zubair S, Mahmood A, Gupta P, Khan AA, ...
  • Marongiu L, Donini M, Toffali L, Zenaro E, Dusi S. ...
  • Xin Q, Niu H, Li Z, Zhang G, Hu L, ...
  • Behr M, Wilson M, Gill W, Salamon H, Schoolnik G, ...
  • Gordon SV, Brosch R, Billault A, Garnier T, Eiglmeier K, ...
  • Bonanni D, Rindi L, Lari N, Garzelli C. Immunogenicity of ...
  • Romano M, Rindi L, Korf H, Bonanni D, Adnet P-Y, ...
  • Rindi L, Peroni I, Lari N, Bonanni D, Tortoli E, ...
  • Uk L. Cleavage of structural proteins during the assembly of ...
  • Niu H, Peng J, Bai C, Liu X, Hu L, ...
  • Wang X, Zhang J, Liang J, Zhang Y, Teng X, ...
  • Geluk A, Lin MY, van Meijgaarden KE, Leyten EM, Franken ...
  • Taylor JL, Wieczorek A, Keyser AR, Grover A, Flinkstrom R, ...
  • Yuan X, Teng X, Jing Y, Ma J, Tian M, ...
  • Cuccu B, Freer G, Genovesi A, Garzelli C, Rindi L. ...
  • Knudsen NPH, Nørskov-Lauritsen S, Dolganov GM, Schoolnik GK, Lindenstrøm T, ...
  • Zhao HL, Yao XQ, Xue C, Wang Y, Xiong XH, ...
  • Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T. ...
  • Afshar S, Olafsen T, Wu AM, Morrison SL. Journal of ...
  • Bai Y, Shen W-C. Improving the oral efficacy of recombinant ...
  • E. LaVallie, E. DiBlasio, S. Kovacic, K. L. Grant, P. ...
  • Francis DM, Page R. Strategies to optimize protein expression in ...
  • Sørensen HP, Mortensen KK. Advanced genetic strategies for recombinant protein ...
  • Hannig G, Makrides SC. Strategies for optimizing heterologous protein expression ...
  • نمایش کامل مراجع